key: cord-0978735-pj76x5cs
authors: Vesuna, Farhad; Akhrymuk, Ivan; Smith, Amy; Winnard, Paul T.; Lin, Shih-Chao; Scharpf, Robert; Kehn-Hall, Kylene; Raman, Venu
title: RK-33, a small molecule inhibitor of host RNA helicase DDX3, suppresses multiple variants of SARS-CoV-2
date: 2022-03-01
journal: bioRxiv
DOI: 10.1101/2022.02.28.482334
sha: 638f34f6bb9f32b3b6291f8570581285890fb012
doc_id: 978735
cord_uid: pj76x5cs

SARS-CoV-2, the virus behind the deadly COVID-19 pandemic, continues to spread globally even as vaccine strategies are proving effective in preventing hospitalizations and deaths. However, evolving variants of the virus appear to be more transmissive and vaccine efficacy towards them is waning. As a result, SARS-CoV-2 will continue to have a deadly impact on public health into the foreseeable future. One strategy to bypass the continuing problem of newer variants is to target host proteins required for viral replication. We have used this host-targeted antiviral (HTA) strategy that targets DDX3, a host DEAD-box RNA helicase that is usurped by SARS-CoV-2 for virus production. We demonstrated that targeting DDX3 with RK-33, a small molecule inhibitor, reduced the viral load in four isolates of SARS-CoV-2 (Lineage A, and Lineage B Alpha, Beta, and Delta variants) by one to three log orders in Calu-3 cells. Furthermore, proteomics and RNA-seq analyses indicated that most SARS-CoV-2 genes were downregulated by RK-33 treatment. Also, we show that the use of RK-33 decreases TMPRSS2 expression, which may be due to DDX3s ability to unwind G-quadraplex structures present in the TMPRSS2 promoter. The data presented supports the use of RK-33 as an HTA strategy to control SARS-CoV-2 infection, irrespective of its mutational status, in humans.

The causative agent of the worldwide COVID-19 pandemic is the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Vaccines are generally considered as the first line of defense against such a large-scale viral spread. Basically, vaccines prime the host's immune system, which then coordinates a direct attack against specific virions. Indeed, rapid deployment of several safe COVID-19 vaccines has proven very effective in attenuating infections and limiting deaths. Nevertheless, as with all viruses, SARS-CoV-2 has been evolving/mutating and variants that are more transmissible have emerged 1,2 . Moreover, it is possible that the continuous evolution of SARS-CoV-2 will result in a vaccine resistant variant(s) 2 even as the efficacy of vaccines is waning [3] [4] [5] . Accordingly, SARS-CoV-2 will continue to have a major impact on the future of public health if development of alternative therapeutic strategies is not pursued.

Direct-acting antiviral agents (DAAs) and those that are host-targeted antivirals (HTAs) have been developed into effective alternatives to vaccine resistance or for use in combination with vaccinations 6 . Here, we have used a HTA directed against the human host DEAD (Asp, Glu, Ala, Asp)-box RNA helicase, DDX3 (DDX3X) and demonstrated a potential of providing an anti-SARS-CoV-2 therapy. We developed a small molecule inhibitor of DDX3, RK-33, that is designed to be a competitive inhibitor of DDX3's ATP binding site and has been demonstrated to abrogate its RNA helicase function [7] [8] [9] which is required for the translation of complex structured 5'capped mRNAs. Our rationale was based on evolutionary studies of SARS-CoV-2, which have revealed that it is closely related to SARS-CoV with a similar sized genome that has nearly identical organization and hence, replication [10] [11] [12] [13] [14] [15] . SARS-CoV-2 replication initially proceeds through a 5'capdependent translation using the host's translation complexes 16 . Consequently, SARS-CoV-2 also has a 5'capped mRNA genome that requires cap-dependent translation 17 . Given the strong evidence that DDX3 participates in 5'capped translation where it forms functional complexes with several eukaryotic translation initiation co-factors including eIF4E, eIF4F, eIF4G and eIF3 [18] [19] [20] [21] and is a required functioning unit in promoting translational as a part of the 80S translation initiation complex 18 , it follows that DDX3 would be utilized in the translation of the SARS-CoV-2 genome. Consistent with this line of reasoning, recent proteomics analyses found DDX3 colocalized with SARS-CoV-2 viral particles and the latter required DDX3 for virion production 22 , DDX3 interacted with SARS-CoV-2 RNA 23 , and that DDX3 was part of the SARS-CoV-2 interactome 24 .

Similarly, DDX3 also participates in the resolution of both RNA and DNA G-quadraplex structures and such structures have been predicted to form in the SARS-CoV-2 genome 25-27 , in the promoter region of the host TMPRSS2 gene 28 , as well as in the 5'UTR of the TMPRSS2 transcript. TMPRSS2 expression is also required for SARS-CoV-2 entry into cells [29] [30] [31] . In addition, three related lines of evidence indicate that DDX3

can be considered as a prime host protein to target 32 : a) several viruses (18 species from 12 genera and 11 families) have been demonstrated as requiring DDX3 for efficient virion production; b) investigators have actively pursued the targeting of DDX3 with small molecule inhibitors as an antiviral strategy [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] ; and c) RK-33 has effectively been used to target DDX3 and abrogate virion production in Dengue, West Nile, Zika, Respiratory Syncytial, and human Parainfluenza Type-3 viral infections 40 .

Our results indicate that regardless of the SARS-CoV-2 isolate (Lineage A, and Lineage B Alpha, Beta, and Delta variants), RK-33 treatment of Calu-3 cells infected with these isolates display significantly reduced viral load by one to three log orders. Consistent with this finding, proteomics and RNA-seq analyses of the infected/RK-33 treated cells demonstrated the downregulation of most of the SARS-CoV-2 proteins and genes and host TMPRSS2 expression was decreased as well. Collectively, the data obtained indicates that the use of RK-33 to abrogate host DDX3 functions is a viable option for the treatment of SARS-CoV-2 infection as well as subsequent variants that may arise.

To study the effect of RK-33 and SARS-CoV-2 on the human transcriptome, we performed RNA-seq on isolated RNA from uninfected Calu-3 cells treated with DMSO (DMSO control), cells treated with RK-33 (RK-33 treated DMSO control), cells infected with SARS-CoV-2 and treated with DMSO (Virus), and cells infected with SARS-CoV-2 and treated with RK-33 (RK-33 treated virus). A non-toxic dose of RK-33 (5 µM) was used for these studies and cells were infected at a MOI of 0.1. All samples were collected at 48 h post infection (hpi).

RNA-Seq was mapped separately to human genome and SARS-CoV-2 genome. Principal Components Analysis (PCA) of host RNA showed a good separation between the infected samples and the control treated samples, while the RK-33 treated samples were clustered together. As expected, RK-33 and SARS-CoV-2 infection were the drivers for sample segregation (Figure 1a and S1). Hierarchical clustering separated all RNA Figures S2 and S3 . Analysis of genes dysregulated by SARS-CoV-2 infection and RK-33 treatment expectedly showed a larger effect ( Figure S3 ). We also compared our gene set with published data 45 which showed a large commonality both in Calu-3 gene sets and in the deceased COVID-19 lung tissue set ( Figure S4 ). In addition, RNA-seq QC results indicated that all samples had around 45 million clean reads, but alignment QC indicated SARS-CoV-2 infected Calu-3 cells had around 33% unique matches in the human genome compared to the rest of the samples at 88% ( Figure S5 ). This is an important result, as it is known that the Nsp1 degrades host RNA so that it can hijack the host cell 46 . This reversion of viral to host RNA in the RK-33 treated SARS-CoV-2 infected cells demonstrates the role of DDX3 in SARS-CoV-2 replication and the importance of targeting DDX3 by RK-33.

To study changes in the human and viral proteome after infection with SARS-CoV-2 and RK-33 treatment, we performed proteomics analysis on SARS-CoV-2 infected Calu-3 cells treated with DMSO solvent control (Virus) and on the RK-33 treated and virus infected Calu-3 cells (RK-33 treated virus) as described above.

Other controls used were uninfected Calu-3 cells treated with RK-33 (RK-33 treated DMSO control) and Calu-3 Subsequently, we performed pathway analysis using Reactome to compare RK-33 treated infected cells with control infected cells. The five most significant pathways that were enriched following SARS-CoV-2 infection were interferon alpha/beta signaling, ISG15 antiviral mechanism, viral mRNA translation, SRPdependent cotranslational protein targeting to membrane, and peptide chain elongation (Figure 2h ). In Figure S8 ). These data indicate that RK-33 treatment suppresses viral protein production corresponding to changes in the host proteomic landscape especially as it relates to innate immune response pathways.

Given that DDX3 has been shown to play a regulatory role in the viral biogenesis, we initially tested the impact of RK-33 on coronavirus replication using human coronavirus OC43 (betacoronavirus) as a BSL-2 model of SARS-CoV-2. The CC50 value of RK-33 on Rhabdomyosarcoma (RD) muscle cells (highly susceptible to HCoV-OC43 infection), was determined to be 3.22 µM (Figure 3a ). Next the antiviral impact of RK-33 was tested on RD cells using non-toxic concentrations of RK-33 (0.1 and 1 µM). Treatment with 1 µM of RK-33 decreased HCoV-OC43 infectious titers by over 100-fold (>~2 logs) ( Figure 3b ). As can be seen in Figure 3c , HCoV-OC43 infection of RD cells results in extensive cytopathic effect (CPE) by 4 dpi (left panel) that was partially relieved by 1 µM of RK-33 treatment (right panel). In addition, treatment with 1 µM of RK-33 decreased HCoV-OC43 infectious titers by over 100-fold (>~2 logs) ( Figure 3b ). These data indicate that RK-33 is effective against a betacoronavirus, which encouraged us to test its impact on SARS-CoV-2.

Thus, since in our study we used Calu-3 cells (lung cancer cell line) as a model cell line for SARS-CoV-2 infection, our initial step in antiviral testing was to establish the CC50 of RK-33 in Calu-3 cells. For this purpose, cells were incubated with RK-33 in concentrations ranging from 0.39 to 50 µM for 24 h. Likewise, RK-33 treatment also resulted in a reduction of ~2.5-3 log10 of intracellular viral RNA production as measured by RT-qPCR analysis using primers recognizing RdRp and E genes/regions ( Figure 3g ). Finally, a one log reduction in extracellular viral RNA (from cell-free supernatants) was also observed (Figure 3h) in RK-33 treated samples.

Along with its worldwide spread, SARS-CoV-2 virus has mutated resulting in genome-wide amino acid variations across the four variants of varying lineages as displayed in Figure 4a . Protein N in the Alpha and Delta variants shows greater divergence from Lineage A than the spike proteins of these same variants.

Proteins E, nsp7, and ORF3a have diverged more than the spike in the Beta variant, and the Delta variant displays some level of divergence from Lineage A in the M, nsp2, nsp4, nsp6, and NendU proteins. Due to large deletions and a frameshift, the ORF8 protein in the Delta variant has diverged from Lineage A to a greater extent than spike protein (https://covariants.org/ and Supp. Table 1 ). Furthermore, Figure 4b displays amino acid substitutions and deletions with respect to the Lineage A variant in sixteen of the proteins. This includes large truncations in ORF7a (Beta and Delta variants) and ORF8 (Alpha variant) and a high number of variations in the hACE2 receptor-interfacing spike proteins. Spike protein amino acid substitutions and deletions with respect to Lineage A variant are further visualized along the protein sequence at higher resolution in Figure 4c . These variations occur throughout the spike protein molecular structure, including within the S1-receptor-binding-domain as seen in the 3D models in Figure 4d . Details of mutations can be found in Supp. Table 1 .

Due to the diversity between different viral variants, we next tested the effect of RK-33 on replication and virion production of different of SARS-CoV-2 variants. RK-33 treatment of cells resulted in a significant reduction (3) (4) log fold) of infectious titers of the Alpha, Beta, and Delta variants ( Figure 5a ). Analysis of the intracellular and extracellular RNA (RdRp and E genes) also showed significant difference between RK-33 treated and DMSO control samples in the amount of the viral RNA production (Figure 5b -g). In conclusion, RK-33 displayed potent antagonistic SARS-CoV-2 effects against all tested variants.

The transmembrane serine protease TMPRSS2 has been identified as the protease that cleaves spike protein of SARS-CoV-2 thus facilitating entry 30 . To determine if abrogating DDX3 activity by RK-33 would affect TMPRSS2 expression, we treated Calu-3 cells with different concentrations of RK-33 for 48 h and probed for the levels of TMPRSS2 and DDX3 by immunoblotting. As shown in Figure 6a , RK-33 at 7.5 µM (CC25) was able to reduce TMPRSS2 expression by 60% percent, quantified using Fiji (ImageJ). To determine if the decrease in TMPRSS2 level by RK-33 had any biological significance on viral entry, we treated Calu-3 cells with RK-33 for 24 h, followed by infection with a SARS-CoV-2 Spike-pseudotyped GFP lentivirus construct.

Two days following infection, we counted the GFP cells using a random unbiased approach. As shown in Figure 6b , use of RK-33 at CC5 (3 µM), reduced the infected cell numbers by 50%. This supports our Discussion SARS-CoV-2 has been successfully targeted in a few ways. Prophylactic vaccines are available that reduce/eliminate hospitalization and associated medical complications due to COVID-19. Presently, other treatments are limited to the antiviral nucleoside analog Remdesivir from Gilead Biosciences and a monoclonal antibody cocktail from Regeneron. However, Remdesivir is only prescribed in severe cases, and both require intravenous infusion making it difficult to obtain without hospitalization. Moreover, Remdesivir has shown mixed results in reducing the time to recovery in hospitalized patients [48] [49] [50] [51] [52] . Another nucleoside analog drug Molnupiravir (EIDD-2801) from Merck is in the process of FDA approval which reduces the risk of hospital admission or death by approximately 50% in patients at risk for poor outcomes 53 .

On the other hand, identifying virus-host interacting factors could reveal new targets to mitigate medical complications associated with SARS-CoV-2 infection. Over the years, several roles of a host protein, DDX3, have been identified as crucial for replication and production of many viruses 54, 55 . Interestingly, DDX3 has also been identified, using proteomics, to be involved in SARS-CoV-2 replication 54,55 . Moreover, computational and system biology approaches have indicated different proteins of SARS-CoV-2 to be associated with cellular organelle functions that are regulated by DDX3 activity 56 . In this study, we used a small molecule inhibitor of DDX3, RK-33, to study its impact of SARS-CoV-2. Using the Lineage A variant, we showed that RK-33 reduced viral titers by over 10,000-fold by plaque assay. These data were further validated by RT-qPCR (RdRp and envelope) of the intra-and extracellular SARS-CoV-2 RNA of the RK-33 treated Lineage A infected Calu-3 cells. This work is in agreement with a study showing that inhibition of DDX3 by two different DDX3 inhibitors, RK-33 and C-4B, impacted SARS-CoV-2 RNA production, but this study did not determine the impact on viral titers 54 .

Based on this encouraging finding, we performed RNA-seq and proteomics analysis on SARS-CoV-2 infected Calu-3 cells, before and after RK-33 treatment. PCA of the RNA showed the major effect of RK-33 on the cells. It was interesting to note that in the virus infected Calu-3 cells, more than 80% of the RNA species was that of SARS-CoV-2, while in the RK-33 group, the host mRNA species was 80% represented. This is indicative that perturbing DDX3 by RK-33 restored many of the host cellular functions while suppressing SARS-CoV-2 replication. This could be clearly seen in both the heat map and the PCA plot with RK-33 treatment serving to "normalize" expression of the virus infected cells towards the uninfected cell type gene expression. Volcano plots also demonstrated how the high gene expression patterns caused by the virus infection were modulated by RK-33 treatment of the cells. Given that the sensitivity of RK-33 to reduce Lineage A titers is indicative of the potential of targeting host proteins for SARS-CoV-2 treatment.

To further characterize the effect of RK-33 on the host cellular machineries, we performed proteomics on SARS-CoV-2 infected Calu-3 cells. Proteomic-based PCA analysis showed that RK-33 treated virus infected samples segregated from the untreated infected samples. The results indicated that RK-33 was the major determinant of segregation in the PCA plot. Subsequent pathway analysis showed that many of the downregulated pathways were associated with virus attachment, entry, assemble and release. Proteomics analysis clearly demonstrated that most of the proteins involved in SARS-CoV-2 genome replication and transcription (ORF1 ab, ORF3A, Spike, Membrane, ORF7A and Nucleoprotein) were significantly downregulated by RK-33 in SARS-CoV-2 infected Calu-3 cells. The ability of RK-33 to reduce viral titers of SARS-CoV-2 Lineage A could reflect on the dependence of SARS-CoV-2 on DDX3 for its replication. This is probably because at the molecular level SARS-CoV-2 usurps DDX3 in the host cell to its advantage for replication and for pathogenesis. This is in parallel to what is already demonstrated by many other viruses that utilize DDX3 for viral entry, processing, and egress from the host cells 57 . Furthermore, as DDX3 has been shown to interact with nucleocapsid protein of SARS-CoV-2 54 , it is plausible that the use of RK-33 is directly interfering with SARS-CoV-2 replication machinery as well.

Based on these promising results, we evaluated the effect of RK-33 on viral titers in the Alpha, Beta, and Delta variant infected cells. RK-33 was able to reduce the viral loads by 200,000, 125,000, and 2,500-fold respectively. This is not unexpected as targeting host factors essential for viral replication, such as DDX3, would have similar outcomes for all the variants. As is evident from the spike protein modeling, there is a higher concentration of spike protein mutation within the ACE-2 binding region, but this does not affect the ability of RK-33 to reduce viral titers across all the variants. Also, the amino acid substitutions lead to increased evolutionary distances in different proteins among the four isolates used in this study. Thus, the four variants used in this study could serve as diverse models adapted to provide a growth advantage or independent evolution of SARS-CoV-2 leading to increased virulence and pathogenesis.

Furthermore, we showed that RK-33 was able to reduce TMPRSS2 expression in Calu-3 cells. A key aspect of the TMPRSS2 gene is the presence of guanine-rich tracts of DNA in its gene promoter that can form G-quadruplex structures. These structures can be targeted by benzoselenoxanthene derivatives that stabilize TMPRSS2 G-quadruplexes in vitro, thus downregulating TMPRSS2 gene expression 58 . In this context, DDX3 was found to facilitate both translation of general complex secondary structures including G-quadruplexes 59,60 , as well as mRNAs with secondary structure in immediate vicinity to their m 7 GTP cap 61 . We have presented data that demonstrates that use of RK-33 even at CC5, reduced the SARS-CoV-2 infection rate by 50%.

These data indicate that targeting DDX3 by RK-33 for SARS-CoV-2 treatment could potentially reduce SARS-CoV-2 virulence and pathogenicity by two different mechanisms. First, it can decrease the infection rate by downregulating TMPRSS2 protein expression, and second, reduce the pathogenicity, by suppressing SARS-CoV-2 replication. This two-prong mechanism of action would be extremely effective at suppressing viral replication of any newly emerging variants of concern, which is in line with an antiviral that is targeting a host factor. We fully appreciate that the impact of RK-33 on TMRPSS2 expression is only one mechanism by which RK-33 may be impacting SARS-CoV-2 production. Indeed, our proteomic and transcriptomic analysis points to multiple cellular events being altered in infected cells by RK-33 treatment, such as innate immune responses, translation, and membrane trafficking, each of which are important for viral production.

In conclusion, we report on the importance of DDX3 and its targeting by the small molecule inhibitor RK-33 which was developed earlier by rational drug design that resulted in a unique structural scaffold with little or no toxicity in animals [7] [8] [9] 62 . Use of RK-33 on Calu-3 cells resulted in suppressing virus titers from all four isolates and has the potential to treat SARS-CoV-2 infection. We are the first to present a promising HTA strategy to tackle the different variants associated with SARS-CoV-2 as well as subsequent variants that may arise.

RK-33 was dissolved in 100% DMSO to the final 10 mM concentration. For a cell-based assay the stock was diluted in complete cell media to required concentrations.

Calu-3 (ATCC HTB-55) and Vero (ATCC CCL-81) cells were cultured at 37 o C and 5%CO2 in EMEM and DMEM, respectively, supplemented with 10% FBS, 1% L-glutamine, and 1% penicillin-streptomycin. The following SARS CoV-2 isolates, obtained from BEI Resources, were used in the study: Lineage A (NR-52281), Beta variant (NR-54008), Alpha variant (NR-54000), Delta variant (NR-55611).

For CC50 assays cells were maintained as described above in 96-well white well plates for 24 h prior to RK-33 

Total RNA was extracted from virus containing cell lysates using Trizol LS (Invitrogen, Carlsbad, CA) and purified using a column purification method (Qiagen, Germany) in accordance with manufacturer's recommendations that were modified to isolate both small and large RNA species. RNA concentration and preliminary quality control was estimated on a NanoDrop spectrophotometer (ThermoFisher Scientific) while RNA-Seq was performed commercially (BGI Americas, San Jose, CA) as detailed in Supplementary Methods. 

Viral RNA was extracted from virus containing cell media and from cell lysates using Trizol LS (from Invitrogen, cat# 10296010) and purified by Direct-Zol RNA purification kit (from Zymo research, cat#R2052) in accordance with manufacturer's recommendations. SARS-CoV-2 RNA (RdRp and E genes) was amplified by the one-step Logix Smart-2 COVID-19 real-time PCR reagents kit from Co-Diagnostics, Inc. (Salt Lake City, UT, USA).

Normalization was performed using RNaseP gene amplified from host RNA. Copy numbers were estimated based on the included quantified positive control reagent.

The genome sequence of the Lineage A variant was retrieved from GenBank accession MW811435, a direct submission of NR-52281 sequencing at ATCC. The Alpha variant genome sequence was retrieved from GenBank accession MZ376737. The Beta variant genome sequence was retrieved from GenBank accession MZ345001. The Delta variant genome sequence was reconstructed from GenBank accession MN908947 with 16 variations as reported on the NR-55611 Certificate of Analysis. Of particular note is a deletion within ORF7a (AA 44-100) with a frameshift that results in extension of the protein sequence with a new stop codon downstream of ORF7b.

Protein sequences for 25 SARS-CoV-2 proteins were extracted from the four genome sequences. For each protein, a four-isolate multiple sequence alignment was performed in CLC Genomics Workbench with a progressive alignment algorithm using default parameters. Differences with respect to the Lineage A variant were noted. Evolutionary distances of proteins were estimated using the WAG substitution model 67 

Total RNA was checked for integrity on a bioanalyser and stranded libraries were constructed from oligo dT purified mRNAs. RNA was fragmented and first-strand cDNA was generated using random N6-primed reverse transcription, followed by a second-strand cDNA synthesis with dUTP instead of dTTP. The synthesized cDNA was subjected to end-repair, 3' adenylated, and adaptors were ligated to cDNA fragments. The dUTP-marked strand was degraded by Uracil-DNA-Glycosylase (UDG) and the remaining strand was PCR amplified to generate a cDNA library. After heat denaturation of the library, the single strand DNA was cyclized by splint oligo and DNA ligase. This is followed by rolling circle replication and DNA nanoball synthesis and eventually sequencing on the DNBSEQ (DNBSEQ Technology) platform.

Quality control (QC) was then performed on the raw reads to determine whether the sequencing data is suitable for subsequent analysis. After QC, the filtered clean reads were aligned to the reference human genome (hg38) using HISAT2 and the statistics of the mapping rate and the distribution of reads on the reference sequence were used to determine whether the alignment result passes the second QC of alignment using FastQC. This was followed by gene quantification analysis and other analysis based on gene expression such as PCA, correlations, and differential gene screening using DeSEQ2. We also performed significant enrichment analysis of GO function on differentially expressed genes and significance enrichment analysis of pathways analysis using REACTOME.

Proteins (50 ug 

Scatterplot displaying the QC of the RNA-seq of all the samples mapped to the human genome. Left Y-axis displays the percent of uniquely mapping reads (green) and the right Y-axis displays total reads in millions (blue). Table S1

A list of defining mutations present in the Alpha, Beta, Delta, and Omicron variants of SARS-CoV-2. Figure S1 a. Figure S9 

Molecular level dissection of critical spike mutations in SARS-CoV-2 variants of Concern (VOCs): A simplified review

N-terminal domain of SARS CoV-2 spike protein mutation associated reduction in effectivity of neutralizing antibody with vaccinated individuals

Effectiveness of COVID-19 vaccines in preventing SARS-CoV-2 infection among frontline workers before and during B.1.617.2 (Delta) variant predominance -Eight

Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar

Waning Immunity after the BNT162b2 Vaccine in Israel

Host-Directed Antiviral Therapy

Targeting DDX3 with a small molecule inhibitor for lung cancer therapy

Targeting mitochondrial translation by inhibiting DDX3: a novel radiosensitization strategy for cancer treatment

RK-33 Radiosensitizes Prostate Cancer Cells by Blocking the RNA Helicase DDX3

COVID-19, SARS and MERS: are they closely related?

A conserved RNA pseudoknot in a putative molecular switch domain of the 3'-untranslated region of coronaviruses is only marginally stable

Discontinuous subgenomic RNA synthesis in arteriviruses is guided by an RNA hairpin structure located in the genomic leader region

The structure and functions of coronavirus genomic 3' and 5' ends

The Proteins of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS CoV-2 or n-COV19), the Cause of COVID-19

Coronaviridae Study Group of the International Committee on Taxonomy of, V. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2

Blocking eIF4E-eIF4G interaction as a strategy to impair coronavirus replication

The DEAD-box helicase DDX3 supports the assembly of functional 80S ribosomes

Human DDX3 functions in translation and interacts with the translation initiation factor eIF3

Critical roles of RNA helicase DDX3 and its interactions with eIF4E/PABP1 in stress granule assembly and stress response

The role of the DEAD-box RNA helicase DDX3 in mRNA metabolism

Proteomic analysis identifies the RNA helicase DDX3X as a host target against SARS-CoV-2 infection

Human DDX3 protein is a valuable target to develop broad spectrum antiviral agents

DDX3X Helicase Inhibitors as a New Strategy To Fight the West Nile Virus Infection

DDX3X inhibitors, an effective way to overcome HIV-1 resistance targeting host proteins

Synthesis and Antiviral Activity of Novel 1,3,4-Thiadiazole Inhibitors of DDX3X

DEAD-box RNA Helicase DDX3: Functional Properties and Development of DDX3 Inhibitors as Antiviral and Anticancer Drugs

DDX3 inhibitors show antiviral activity against positive-sense single-stranded RNA viruses but not against negative-sense single-stranded RNA viruses: The coxsackie B model

RK-33 Is a Broad-Spectrum Antiviral Agent That Targets DEAD-Box RNA Helicase DDX3X

Viruses and the human DEAD-box helicase DDX3: inhibition or exploitation?

RNA helicase DDX3: at the crossroad of viral replication and antiviral immunity

Reactome pathway analysis: a high-performance in-memory approach

The reactome pathway knowledgebase

Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19

SARS coronavirus nsp1 protein induces template-dependent endonucleolytic cleavage of mRNAs: viral mRNAs are resistant to nsp1-induced RNA cleavage

STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets

Remdesivir against COVID-19 and Other Viral Diseases

Comparison of Time to Clinical Improvement With vs Without Remdesivir Treatment in Hospitalized Patients With COVID-19

Remdesivir for the Treatment of Covid-19 -Final Report

Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial

Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebocontrolled, multicentre trial

Covid-19: Molnupiravir reduces risk of hospital admission or death by 50% in patients at risk, MSD reports

Proteomic analysis identifies the RNA helicase DDX3X as a host target against SARS-CoV-2 infection

Host DDX Helicases as Possible SARS-CoV-2 Proviral Factors: A Structural Overview of Their Hijacking Through Multiple Viral Proteins

Comparative host-coronavirus protein interaction networks reveal pan-viral disease mechanisms

Targeting host DEAD-box RNA helicase DDX3X for treating viral infections

Inhibition of Influenza A virus propagation by benzoselenoxanthenes stabilizing TMPRSS2 Gene G-quadruplex and hence down-regulating TMPRSS2 expression

The DEAD-box RNA helicase DDX3 associates with export messenger ribonucleoproteins as well as tip-associated protein and participates in translational control

DDX3 regulates cell growth through translational control of cyclin E1

DEAD-box protein DDX3 associates with eIF4F to promote translation of selected mRNAs

Broad Spectrum Anti-Cancer Agents Containing the Tricyclic 5:7:5-Fused Diimidazodiazepine Ring System

Assessment of plaque assay methods for alphaviruses

Two Detailed Plaque Assay Protocols for the Quantification of Infectious SARS-CoV-2

Reversed-phase chromatography with multiple fraction concatenation strategy for proteome profiling of human MCF10A cells

Statistical inference from multiple iTRAQ experiments without using common reference standards

A general empirical model of protein evolution derived from multiple protein families using a maximum-likelihood approach

S:A701V ORF1b:P314L S:L212I A28271T ORF1a:T1001I ORF3a:Q57H ORF1b:G662S S:G339D ORF1a:A1708D ORF1a:T265I ORF1b:P1000L S:S371L ORF1a:I2230T ORF1a:K1655N M:I82T S:S373P ORF1a:S3675-ORF1a:K3353R N:D63G S:S375F ORF1a:G3676-ORF1a:S3675-N:R203M S:K417N ORF1a:F3677-ORF1a:G3676-N:D377Y S:N440K N:D3L ORF1a:F3677-ORF3a:S26L S:G446S N:R203K N:T205I ORF7a:V82A S:S477N N:G204R ORF1b:P314L ORF7a:T120I S:T478K N:S235F E:P71L ORF8:D119-S:E484A ORF1b:P314L ORF8:F120-S:Q493R ORF8:Q27* ORF9b:T60A S:G496S ORF8:R52I S:Q498R ORF8:Y73C S:N501Y S:Y505H S:T547K S:D614G S:H655Y S:N679K S:P681H S:N764K S:D796Y S:N856K S:Q954H S:N969K S:L981F N:P13L N:E31-N:R32-N:S33-N:R203K N:G204R ORF1a:K856R ORF1a:S2083-ORF1a:L2084I ORF1a:A2710T ORF1a:T3255I ORF1a:P3395H ORF1a:L3674-ORF1a:S3675-ORF1a:G3676-ORF1a:I3758V ORF1b:P314L ORF1b:I1566V ORF9b:P10S ORF9b:E27-ORF9b:N28-ORF9b:A29-E:T9I M:D3G M:Q19E M:A63T

The following SARS-CoV-2 isolates were obtained through BEI Resources, NIAID, NIH: SARS-Related We wish to acknowledge the NIH (Grant R01CA207208) and FAMRI for funding to VR. Support was also provided by Drs. Bhujwalla and Horton and the Department of Radiology.

VR holds a patent on the composition of RK-33 (US patent # 8,518,901